Sionna TherapeuticsSION
Recorded

Sionna Therapeutics Stifel 2026 Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration21 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Paul MatteisAnalyst

All right. Thanks, everybody. Happy to be here with the Sionna Therapeutics team. With me is Mike Cloonan, CEO, Elena Ridloff, CFO. Always great to see you guys.

Paul MatteisAnalyst

You too, Paul. We'll dig into next steps for NBD1, but maybe I'll turn it over to Mike briefly, just make some quick opening remarks, and maybe Elena, you could chime in too, just on the balance sheet and cash runway as well.

Mike CloonanCEO

Yeah, great. First, thanks, Paul, and thanks, Stifel, for inviting us. Always great to be with you and to be here at the conference. Just for way of background to kick this off, Sionna is focused on cystic fibrosis. We're focusing on a differentiated target in NBD1, as Paul just said, and our goal and our mission is to provide new meaningful options to people living with CF. We know there's unmet need that exists today. We believe NBD1 has the potential to be disruptive in a very positive way in the CF market. We'll talk today about our plans coming off of the PreciSION data now three months ago, and our plans for the AscenSION CF study, which will be our proof of concept.

Mike CloonanCEO

Sorry, Paul. Yeah. Okay. We will be starting our AscenSION CF study in the first quarter of this year.

Mike CloonanCEO

Looking forward to kicking that study off, which will be our two-drug combination of SION-451 and SION-2222. Again, we think we will have the opportunity to drive to a meaningful new option for patients and an opportunity for us to demonstrate the power of NBD1. I will let Elena talk a little bit about our cash runway and some of the plans.

Elena RidloffCFO

Yeah. We actually announced our third quarter earnings this morning. We ended the third quarter with $250 million in cash, and we have cash runway into the second half of 2029. So we are well-funded today, and as Mike was articulating, we are going to be initiating the first quarter of next year our dual combination study with SION-451 and SION-2222. I am sure we will get more into that.

Paul MatteisAnalyst

Yep. Okay, great. Well, maybe to level set, you have had some time now since the phase IIa readout, so obviously the study did not meet your goal. There were some signs of drug activity. Do you want to talk about the different sort of theories you have come up with to explain the result? I have asked you this, and I do not know if it is fair, but people ask you this all the time, how do you sort of rank order them and kind of make sense of what the most likely explanation is here?

Mike CloonanCEO

Yeah, so I'll start that, Paul. Yes, it's been three months since we announced the PreciSION CF study. Obviously, very disappointed with the results. We felt we had a real opportunity to demonstrate the NBD1 biology and that this combination of SION-719 plus the components of TRIKAFTA would be synergistic and potentially add meaningful benefit to people living with CF. If you step way up, again, that concept of how we initiated that study and why we chose SION-719 and that add-on to TRIKAFTA was we believed there would be synergy. We thought the correction of NBD1, correcting the other part of the protein that TRIKAFTA does not correct, we would have this synergistic four-drug combination that would be beneficial for patients.

Mike CloonanCEO

When we stepped back and looked at the data, what we think happened was the actual opposite of that there was anti-synergy of adding SION-719 to TRIKAFTA, and we'll talk about that. To your point, Paul, there were three different takeaways that we had when we did our post hoc analysis on the PreciSION dataset. The first was when we did a deep dive into the PK and the sweat chloride results, we saw what we believe was clear evidence of non-adherence. Unfortunately, there were three patients that, in the study, looked like they had been non-adherent to either TRIKAFTA during the washout period when they were only on TRIKAFTA, and there was one patient during the time when they were treated with SION-719 that looked like they were non-adherent for some period of time on SION-719.

Mike CloonanCEO

That clearly had an impact on the results, and so we ran that dataset by the Cystic Fibrosis Foundation, our clinical advisory board, our primary investigator, because what you don't want to do is cherry-pick, right? We weren't looking to cherry-pick the data out of this and try to save the study. What we really tried to understand is, do we see activity, NBD1 activity in the study? That first assessment of the non-adherence was important because when we did the post hoc and we re-ran the sweat chloride numbers, removing those three subjects, what we saw was a sweat chloride improvement of somewhere between four and nine, depending on whether we used the primary or the secondary analysis.

Mike CloonanCEO

With that data, and when we looked at the participants who we kept in the study, not removing them, what we saw, the distribution of sweat chloride results and the placebo effect, it looked like target engagement. We could see evidence of NBD1 doing something, although not to the expectation that we had. As everybody remembers, we had set a target of at least 10 is what we expected to have in that study. Even with the removal of those non-adherent patients, we weren't achieving that, but it was still important because we could see that target engagement, that NBD1 was doing something. The second question was, why are we not getting the 10 when we had such a strong belief in what we were going to deliver? That gets to that anti-synergy.

Mike CloonanCEO

There were actually two other factors when we did the post hoc that we think was the interaction of 719 plus TRIKAFTA. The first, which you and I have talked a little bit about, was the PK interaction that we saw, that when we looked at when patients were just on TRIKAFTA during the period of time, there were different points when they're either in the washout period or they're just on TRIKAFTA. We measure their PK, and over that period of time when they were just on TRIKAFTA, their TRIKAFTA exposure levels stayed consistent. But the difference we saw is in the period of time when they were treated with 719 and TRIKAFTA, the TRIKAFTA exposure levels dropped on average 25% to 30% across the components of TRIKAFTA.

Mike CloonanCEO

We saw this PK interaction, which was very different than what we expected, because as you may remember, we did our DDI study ahead of the PreciSION CF study to confirm we would not have an impact on TRIKAFTA, specifically as it relates to CYP3A4. That's the DDI we were looking at prior to the study. We do not believe this PK interaction is CYP3A4. We think there's something else going on with this four-drug combination that's hard to explain with the data that we have. And the only way we could understand it is if you did more work and more studying of this four-drug combination, which we're not going to do.

Mike CloonanCEO

But that was truly a confounder and hard to quantify what impact that could have on sweat chloride, but not unreasonable to think that if TRIKAFTA's levels are coming down when treated with 719, could that be enabling sweat chloride to drift back up and in some ways mask the benefit of NBD1?

Paul MatteisAnalyst

Yeah. And you guys have tried to dig into whether there's any withdrawal data or anything like that. We can try to quantify it theoretically, but there's really nothing tangible out there?

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day